Allergan to Share New Data Highlighting Latest Advancements in Eye Care at ARVO 2021

Allergan announced that it will present new data, including real-world evidence, and patient-reported outcomes (PROs) for products across its eye care portfolio and pipeline at the ARVO (Association for Research in Vision and Ophthalmology) 2021 Annual Virtual Meeting (May 1-7).

“We are excited to present a range of data that will help us better understand not just how our portfolio performs in the clinic, but also the real-world experiences of our patients,” Michael R. Robinson, MD, vice president, global therapeutic area head, eye care, AbbVie. “The diversity of our data at ARVO 2021 demonstrates how Allergan Eye Care is advancing potential treatments for patients living with a number of difficult-to-treat eye diseases including presbyopia and retina diseases such as age-related macular degeneration.”

The company will present patient-reported outcomes for AGN-190584, an investigational therapy for the treatment of presbyopia. Recently the company submitted a new drug application (NDA) to the FDA based on data from the phase 3 GEMINI 1 and GEMINI 2 clinical studies.

Data presented at the meeting will also include new analyses from the phase 3 ARTEMIS studies examining the duration of IOP lowering and biodegradation kinetics of Durysta.

Additionally, real world data from the multicenter EXPAND study, evaluating 12-month outcomes of an investigation into a novel placement of the XEN Gel Stent will be presented at the meeting. The XEN Gel Stent is currently approved only for ab-interno placement.

The ARVO 2021 Annual Virtual Meeting abstracts can be viewed at https://arvo2021.arvo.org/agenda.

Details about the presentations are as follows: